1,2-二去甲基神经酰基-sn-甘油-3-磷酸胆碱 | 91742-11-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: 1,2-二去甲基神经酰基-sn-甘油-3-磷酸胆碱
• 英文名称: 1,2-dilignoceroyl-sn-glycero-3-phosphatidylcholine
• 英文别名: L-α--lecithin；1,2-Ditetracosanoyl-sn-glycero-3-phosphocholine；[(2R)-2,3-di(tetracosanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 91742-11-9
• 化学式: C₅₆H₁₁₂NO₈P
• 分子量: 958.481
• InChiKey: XOAMGMFHUNHBEM-AXAMJWTMSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  22.1
• 重原子数：
  66
• 可旋转键数：
  56
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• WGK Germany：
  3
• 储存条件：
  -20°C

反应信息

• 作为产物：
  描述：

  lignoceroyl chloride 、 甘磷酸胆碱 以 氯仿 为溶剂， 生成 1,2-二去甲基神经酰基-sn-甘油-3-磷酸胆碱
  参考文献：
  名称：

  Koegl,F. et al., Recueil des Travaux Chimiques des Pays-Bas, 1960, vol. 79, p. 661 - 674

  摘要：

  DOI：

文献信息

• Compositions and methods for enhancing contrast in imaging
  申请人：Marval Biosciences, Inc.

  公开号：EP2578237A1

  公开（公告）日：2013-04-10

  Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast- enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making liposomes containing high concentrations of contrast-enhancing agents, and example methods for using the compositions.

  本发明提供了一些脂质体组合物实例，这些脂质体表面具有亲水性聚合物，并含有相对高浓度的计算机断层扫描造影剂。这种脂质体的药物组合物范例在给受试者用药时，可使受试者血液和其他组织中的对比度增加，持续时间延长，如计算机断层扫描所测。此外，还提供了制造含有高浓度造影剂的脂质体的示例方法，以及使用这些组合物的示例方法。
• Liposomal mupirocin
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

  公开号：US10004688B2

  公开（公告）日：2018-06-26

  Provided are liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions including the liposomes and methods of using them. The liposomes include a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.

  本文提供的脂质体封装了莫匹罗星，特别有利于全身有效给药。本文还提供了包括脂质体的药物组合物及其使用方法。脂质体包括脂质膜和脂质体内室，脂质体内室包封莫匹罗星、至少一种环糊精化合物和与 pH 值有关的可电离阴离子，如醋酸盐。
• Liposomal formulation of nonglycosidic ceramides and uses thereof
  申请人：LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

  公开号：US10039715B2

  公开（公告）日：2018-08-07

  The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  本发明提供了在其双层内含有非糖苷类神经酰胺的脂质体及其组合物。这些脂质体可在体外和体内激活小鼠 iNKT 细胞并诱导树突状细胞（DC）成熟，其功效与相应的可溶性非糖苷神经酰胺相当。此外，还提供了使用本发明脂质体和组合物治疗疾病的方法。
• Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
  申请人：ModernaTX, Inc.

  公开号：US10172808B2

  公开（公告）日：2019-01-08

  The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

  本公开涉及免疫调节多核苷酸（如mRNA）编码免疫应答引物多肽（如白细胞介素23（IL-23）多肽或白细胞介素36γ（IL-36-γ）多肽）和免疫应答共刺激信号多肽（如OX40L多肽）组合的制备、制造和治疗使用的组合物和方法。
• MRNA combination therapy for the treatment of cancer
  申请人：ModernaTX, Inc.

  公开号：US10335486B2

  公开（公告）日：2019-07-02

  The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.

  本公开涉及使用核酸（如mRNA）组合疗法治疗癌症。本公开提供了组合物及其制备、制造和治疗使用的方法，其中这些组合物包括至少两种组合在一起的多核苷酸（如mRNA），其中至少两种多核苷酸选自由以下组成的组(i)编码免疫应答引物的多核苷酸（如IL23），(ii)编码免疫应答引物的多核苷酸（如IL23），(iii)编码免疫应答引物的多核苷酸（如IL23），(iv)编码免疫应答引物的多核苷酸（如IL23）、IL23），(ii) 编码免疫应答共刺激信号（如 OX40L）的多核苷酸，(iii) 编码检查点抑制剂（如抗 CTLA-4 抗体）的多核苷酸，以及 (iv) 其组合。本文公开的治疗方法包括，例如，在有需要的受试者中施用本文公开的用于治疗癌症的组合疗法，例如，通过减小肿瘤大小或抑制肿瘤生长。在某些方面，本文公开的组合疗法是肿瘤内给药。